LabGenomics
랩지노믹스 · 084650
Industrials Commercial Services · KOSDAQ
Market cap US$48.3M (₩66.6B)
Overview
LabGenomics provides genetic diagnostic testing services, most notably a non-invasive prenatal screening test that checks a mother's blood sample for chromosomal abnormalities in the fetus, avoiding the risks of traditional needle-based procedures.
Its tests are used by expectant mothers and newborns, delivered through a network spanning thousands of medical institutions and specialist obstetrics clinics across South Korea. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core product line is its 'MomGuard' prenatal test suite, which ranges from a standard tier to a premium tier capable of screening for a broad range of chromosomal conditions.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$53M
- FY2024US$62.2M
- FY2025US$63.9M
Operating profit
- FY2023−US$4.9M
- FY2024−US$13.4M
- FY2025−US$38.8M
Net income
- FY2023−US$3.8M
- FY2024−US$17.3M
- FY2025−US$46.6M
Key ratios (FY2025)
Why it matters
The company's genetic test items are registered with Korea's Korea Disease Control and Prevention Agency, a regulatory requirement that governs which tests may be commercially offered domestically.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?